C12Y 301/04012
Sphingomyelin phosphodiesterase
Official title: Sphingomyelin phosphodiesterase (3.1.4.12)
C12Y301/04012 (Sphingomyelin phosphodiesterase) appears on 54 US grants and 106 published applications in this corpus.
Search patents in C12Y- Granted patents
- 54
- Published applications
- 106
- Assignees
- 47
- Inventors
- 141
- Latest grant
- 16 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1999 | 1 | 0 |
| 2000 | 0 | 0 |
| 2001 | 1 | 0 |
| 2002 | 0 | 2 |
| 2003 | 2 | 3 |
| 2004 | 1 | 3 |
| 2005 | 1 | 4 |
| 2006 | 0 | 1 |
| 2007 | 1 | 1 |
| 2008 | 0 | 0 |
| 2009 | 0 | 4 |
| 2010 | 1 | 1 |
| 2011 | 0 | 2 |
| 2012 | 0 | 1 |
| 2013 | 1 | 2 |
| 2014 | 7 | 6 |
| 2015 | 3 | 4 |
| 2016 | 3 | 6 |
| 2017 | 2 | 5 |
| 2018 | 4 | 7 |
| 2019 | 1 | 7 |
| 2020 | 2 | 4 |
| 2021 | 7 | 11 |
| 2022 | 1 | 7 |
| 2023 | 2 | 5 |
| 2024 | 6 | 7 |
| 2025 | 4 | 8 |
| 2026 | 3 | 5 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- RNA preparations comprising purified modified RNA for reprogramming cells16 Jun 2026US 12,655,395 B2
- Marker for acid sphingomyelinase disorders and uses thereof31 Mar 2026US 12,589,138 B2Genzyme Corporation
- Method for treating a degenerative neurological disorders comprising administering ASM inhibitor10 Feb 2026US 12,545,745 B2Kyungpook National University Industry-Academic Cooperation Foundation
- Compositions and methods for activating signaling through the CB1 cannabinoid receptor for treating and preventing diseases and disorders characterized by abnormal cellular accumulation of sphingolipids such as sphingomyelin2 Dec 2025US 12,485,117 B2Wylder Nation Foundation
- Antibody which binds to myelin oligodendrocyte glycoprotein13 May 2025US 12,297,268 B2Kagoshima University
- Rna preparations comprising purified modified rna for reprogramming cells1 Oct 2026US 2026/0297538 A1The Trustees of the University of Pennsylvania
- Compositions and methods for diagnosing, treating, and preventing lysosomal storage diseases24 Sep 2026US 2026/0286363 A1Wylder Nation Foundation
- Oxazole compound and pharmaceutical composition23 Apr 2026US 2026/0108497 A1Otsuka Pharmaceuticalc., Ltd.
- Modified mammalian cells9 Apr 2026US 2026/0098254 A1Genentech, Inc.
- Antibody which binds to myelin oligodendrocyte glycoprotein2 Apr 2026US 2026/0092110 A1Kagoshima University
Most cited
By later US patents
- Compositions and methods for reprogramming eukaryotic cells103US 8,808,982 B2Cellscript, LLC · 2014
- Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency28US 8,349,319 B2Genzyme Corporation · 2013
- Chaperone-based therapy for Niemann-Pick disease24US 7,750,050 B2Mount Sinai School of Medicine of New York University · 2010
- Method for treating a subject suffering from a condition associated with an extracellular zinc sphingomyelinase23US 5,989,803 AThe Trustees of Columbia University in the City of New York · 1999
- Method for treating a subject suffering from conditions associated with an extracellular zinc sphingomyelinase17US 6,613,322 B2The Trustees of Columbia University in the City of New York · 2003